Celularity Inc. (CELU) — 3.64 (+0.67)
Key Metrics & Ratings
- symbol CELU
- Rev/Share 0.0785
- Book/Share 0.1606
- PB 1.747
- Debt/Equity 2.0193
- CurrentRatio 0.1949
- ROIC -1.5966
- MktCap 54375229.0
- FreeCF/Share -0.362
- PFCF -0.7976
- PE -0.2913
- Debt/Assets 0.3886
- DivYield 0
- ROE -1.4418
- Rating A+
- Score 5.0
- Recommendation Strong Buy
- P/E Score 5.0
- DCF Score 5.0
- P/B Score 5.0
- D/E Score 4.0
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
Published: April 15, 2024 by: GlobeNewsWire
Sentiment: Neutral
CELU Announces Net Sales Trending Ahead of Expectations for 1Q '24; Implements Planned '24 SG&A Reductions & Mfg. Ramp for Advanced Biomaterial Products
Read More
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
Published: March 20, 2024 by: GlobeNewsWire
Sentiment: Neutral
Company Has Already Received IND Clearance from the FDA and Plans to Begin Phase 1/2 Study in 2024 with Off-the-Shelf, Placental-Derived Cell Therapy Company Has Already Received IND Clearance from the FDA and Plans to Begin Phase 1/2 Study in 2024 with Off-the-Shelf, Placental-Derived Cell Therapy
Read More
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
Published: March 12, 2024 by: GlobeNewsWire
Sentiment: Neutral
Keynote Will Discuss Cellular Immunotherapy's Potential for Treating Chronic Conditions, Including Cancer, Multiple Sclerosis and Parkinson's Disease Keynote Will Discuss Cellular Immunotherapy's Potential for Treating Chronic Conditions, Including Cancer, Multiple Sclerosis and Parkinson's Disease
Read More
Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline
Published: February 01, 2024 by: GlobeNewsWire
Sentiment: Neutral
Continuing the substantial growth trajectory that began during 2023, for the first quarter 2024 and the full year 2024, Celularity expects triple-digit percentage increases in combined net sales of its advanced biomaterial product and biobanking businesses compared to the first quarter 2023 and the full year 2023.
Read More
Celularity Releases CEO Letter to Shareholders
Published: January 18, 2024 by: GlobeNewsWire
Sentiment: Neutral
FLORHAM PARK, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder, which is included below and can also be accessed here .
Read More
Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare
Published: January 04, 2024 by: GlobeNewsWire
Sentiment: Neutral
FLORHAM PARK, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. (“BioCellgraft”) under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dental/oral healthcare applications. A copy of BioCellgraft's announcement of the agreement can be accessed here: https://www.prweb.com/releases/biocellgraft-finalizes-commercialization-agreement-with-celularity-for-the-manufacture-and-distribution-of-products-for-therapeutic-use-in-oral-healthcare-302025082.html.
Read More
Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023
Published: January 03, 2024 by: GlobeNewsWire
Sentiment: Neutral
Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year 2023 reflecting triple-digit increases compared to the fourth quarter 2022 and full year 2022, respectively. These numbers do not include revenue from other sources, including research contracts such as the Company's previously announced multi-year research collaboration services agreement with Regeneron.
Read More
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Published: November 24, 2023 by: GlobeNewsWire
Sentiment: Neutral
FLORHAM PARK, N.J., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today that on November 21, 2023, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq's continued listing requirements of the Company's failure to timely file a Form 10-Q for the third quarter of 2023.
Read More
About Celularity Inc. (CELU)
- IPO Date 2019-08-08
- Website https://www.celularity.com
- Industry Biotechnology
- CEO Dr. Robert Joseph Hariri M.D., Ph.D.
- Employees 225